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Anthracyclines are commonly used to treat childhood leukemias and lymphomas, as well as other malignancies, leading to
agrowingpopulationoflong-termchildhoodcancersurvivors.However,theiruseislimitedbycardiotoxicity,increasingsurvivors’
vulnerability to treatment-related complications that can markedly aﬀect their quality of life. Survivors are more likely to suﬀer
from heart failure, coronary artery disease, and cerebrovascular accidents compared to the general population. The speciﬁc
mechanisms of anthracycline cardiotoxicity are complex and remain unclear. Hence, determining the factors that may increase
susceptibility to cardiotoxicity isof great importance, asis monitoringpatients during andafter treatment. Additionally, treatment
and prevention options, such as limiting cumulative dosage, liposomal anthracyclines, and dexrazoxane, continue to be explored.
Here, we review the cardiovascular complications associated with the use of anthracyclines in treating malignancies in children
and discuss methods for preventing, screening, and treating such complications in childhood cancer survivors.
1.Introduction
Cancer is diagnosed in more than 12,000 children in the
United States every year [1]. Over the past 25 years, the
5- and 10-year survival rates for childhood cancers have
substantially improved, from less than 50% in the 1970s to
almost 80% today [2, 3]. Some of this improvement comes
from the use of anthracycline chemotherapeutic agents,
which are widely used to treat childhood leukemias and
lymphomas, as well as other malignancies. Their use has
helped create a growing population of long-term childhood
cancer survivors of more than 325,000 in the United States
alone [4]. However, this growing population of survivors
is at a substantial risk for treatment-related complications
that can markedly aﬀect their quality of life. Increasingly,
survivors and their clinicians are realizing the importance of
continuous monitoring long after their cancer treatment has
been completed.
Within the ﬁrst 30 years after diagnosis, 75% of child-
hood cancer survivors will suﬀer from a chronic health
condition [5]. Recent 5-year estimates indicate that the
leading non-cancer-related cause of morbidity and mortality
in long-termsurvivorsofchildhoodcanceriscardiovascular-
related disease [5–10]. Survivors are 8 times more likely than
the general population to die from cardiovascular-related
disease, and compared to sibling controls, they are 15 times
aslikelytosuﬀerfrom heart failure (HF),more than 10times
as likely to have coronary artery disease, and more than 9
times as likely to have had a cerebrovascular accident during
the ﬁrst 30 years after cancer diagnosis [5].
Anthracyclines, such as doxorubicin, are among the
leadingcausesofthesecardiovascular events.The cardiotoxic
nature of anthracyclines, coupled with their widespread use,
may explain the large impact they have made on survivor
morbidity and mortality [11]. Childhood cancer survivors
exposed to anthracyclines are at a signiﬁcantly increased2 Cardiology Research and Practice
risk of HF, and this risk increases as the cumulative dose
increases; 30 years after diagnosis, more than 7.5% will have
experienced HF [7]. The risks of cardiac events persist up to
45 years beyondtreatment and are the second most common
cause of death, after secondary malignancy [12]. Cardiotox-
icity from childhood cancer treatments is a cause for heart
transplantation in young adults [13]. In addition to clinical
outcomes, detailed cardiac evaluations have shown that
more than half of anthracycline-exposed childhood cancer
survivors have subclinical cardiac abnormalities, including
decreased left ventricular (LV) mass and wall thickness,
increased LV afterload, and decreased LV contractility [14].
The severity of the cardiotoxic eﬀects of anthracyclines
vary and are categorized by time of onset as acute, occurring
during or immediately after treatment, early, occurring
within 1yearofexposure, andlate,occurring 1ormoreyears
after initial exposure (Table 1)[ 11,15]. Severe cardiotoxicity,
during or shortly after treatment, is strongly associated with
HF later in life, despite an initial asymptomatic interval. In
a followup study of long-term survivors of childhood cancer
who were treated with anthracyclines and who experienced
acute HF, all had a temporary recovery though nearly half
of these patients later had recurrent HF [14]. Understanding
the early- and late-onset cardiovascular complications of
long-term survivors of childhood cancer is important for
oncologists, cardiologists, and other health care providers
involved in the care of such patients, not only after cancer
treatment but also when selecting treatments at the time of
diagnosis.
Here, we review the cardiovascular complications associ-
ated with the use of anthracyclines in treating malignancies
in children and discuss methods for preventing, screening,
and treating such complications in childhood cancer sur-
vivors.
2.Anthracyclinesand Mechanisms of
Cardiotoxicity
Anthracyclines are commonly used to treat a variety of
solid and hematologic tumors in both adults and chil-
dren. However, because they have clinically relevant dose-
dependent cardiotoxicity, lower doses are used in treating
childhood cancer [18, 19]. Anthracyclines express their
anticancer eﬀects through two major mechanisms: (1) their
intercalationbetweenbasepairsofDNApreventscancercells
from replicating and (2) their inhibition of topoisomerase-
II activity prevents the uncoiling process of DNA that is
necessary for replication and transcription.
However, the speciﬁc mechanisms of anthracycline car-
diotoxicity are complex and, despite decades of research,
remain unclear. The oxidative stress hypothesis is among
the most widely studied and accepted cellular mechanism
thought to cause cardiotoxicity [20–23]. Once administered,
anthracyclines are believed to enter cells through passive
diﬀusion, where they can reach intracellular concentrations
several hundred times higher than that in extracellular
compartments.Onceinsidethecell,anthracyclinesmayform
complexes with intracellular iron, leading to the production
of free radicals, which can cause DNA damage and lipid
peroxidation. The damage caused by free radicals, and by
reactive oxygen species (ROS), can eventually lead to cell
death and larger-scale organ damage.
Why the heart is particularly vulnerable to oxidative
stress caused by anthracyclines is not clear, but the abun-
dance of mitochondria found in cardiomyocytes [5]m a y
be involved. Increasingly, the importance of mitochondria
as key mediators of anthracycline-induced cardiotoxicity has
been reported [24]. Cardiolipin, a phospholipid found in
high concentrations on the inner cell membrane of cardiac
mitochondria, has a high aﬃnity for anthracyclines. This
aﬃnity allows increased concentrations to enter cardiac
mitochondria [25, 26], which may impair membrane stabil-
ity or lead to mitochondrial DNA damage by intercalation.
Anthracycline eﬀects on the mitochondria may also impair
the cell’s ability to produce energy and to handle the added
oxidative stress of cancer and its treatments [21, 27–29].
In addition, one of the heart’s key antioxidants, glutathione
peroxidase, isdepletedinthepresenceofanthracyclines[30].
Several other mechanisms have been suggested for
anthracycline cardiotoxicity, including the induction of
apoptosis, abnormal creatine kinase activity, the production
of vasoactive amines, the formation of toxic metabolites,
upregulation of nitric oxide synthetase, and the inhibition
of transcription and translation [31–33]. Anthracyclines
cause uncoupling of the electron transport chain, which
creates highly reactive oxygen species, and can impair oxida-
tive phosphorylation and adenosine triphosphate (ATP)
synthesis [24]. Anthracyclines can also impair mitochon-
drial calcium homeostasis, leading to the loss of stability
of the mitochondrial membrane, decreased ATP, and cell
death.
In addition, several other changes have been observed
in anthracycline-exposed cardiomyocytes, for which the
underlying mechanisms have yet to be fully explained. These
changes include depleted cardiac stem cells [34], impaired
DNA synthesis [35], impaired cell signaling that triggers cell
death [36], altered gene expression [37], inhibited calcium
release from the sarcoplasmic reticulum [38], impaired for-
mation of the protein titin in sarcomeres [39], and impaired
mitochondrial creatine kinase activity and function [40].
None of these ﬁndings, however, are necessarily completely
dependent or independent of an oxidative stress pathway.
The fact that many of these subcellular consequences con-
tinue to progress for weeks after anthracycline exposure may
provide insight into the mechanisms of chronic cardiomy-
opathy [41].
Finally, understanding cardiovascular cell signaling pro-
teins may prove useful by clarifying both the pathway of
toxicityand theearlydetectionofanthracycline-inducedcar-
diotoxicity.Becauseofthesynergistic cardiotoxicpotentialof
anthracyclinesandtheErbB2antibody, trastuzumab,interest
in the role of neuregulin (NRG-1) is growing. Neuregulin
i sag r o w t hf a c t o rt h a ti sa ne n d o g e n o u sl i g a n df o rt h e
proteinErbB2and is possibly involvedin a signaling pathway
that regulates sarcomere functioning [33]. Neuregulin levels
are decreased with anthracycline use, suggesting a potential
mechanism of toxicity. However, this decrease has notCardiology Research and Practice 3
Table 1: Characteristics and course of anthracycline-induced cardiotoxicity [15].
Characteristics Acute cardiotoxicity Early-onset, chronic progressive
cardiotoxicity
Late-onset, chronic progressive
cardiotoxicity
Onset Within the ﬁrst week of
anthracycline treatment
<1 year after the completion of
anthracycline treatment
≥1 year after the completion of
anthracycline treatment
Risk factor dependence Unknown Yesa Yesa
Clinical features in adults Transient depression of
myocardial contractility Dilated cardiomyopathy Dilated cardiomyopathy
Clinical features in children Transient depression of
myocardial contractility
Restrictive cardiomyopathy and/or
dilated cardiomyopathy
Restrictive cardiomyopathy and/or
dilated cardiomyopathy
Course Usually reversible on
discontinuation of anthracycline Can be progressive Can be progressive
From Adams et al. [15]. Reprinted with permission from John Wiley & Sons, Inc.
aData from Giantris et al. [16], and Grenier and Lipshultz [17].
been clearly associated with serum and echocardiographic
markers of cardiac dysfunction [42].
3.RiskFactorsforAnthracycline-Related
CardiacAbnormalities
Notall children exposed toanthracyclines experience cardiac
abnormalities, and the clinical severity of the abnormalities
that do occur varies greatly between individuals. Hence,
determining the factors that may increase susceptibility
to the cardiotoxic eﬀects of anthracyclines is of great
importance. First, ascertaining which patients are most likely
to experience cardiotoxicity can guide treatment, especially
as long-term health becomes a more prominent treatment
focus. Second, identifying risk factors may help to determine
the mechanisms directly responsible for cardiac damage
and potentially lead to novel strategies for cardioprotection
and treatment. Third, risk stratiﬁcation may help guide the
eﬃcient use of followup screening [22].
One of the main risk factors for anthracycline cardiotox-
icity is high cumulative dose. Since the 1970s, studies have
shown that higher cumulative doses of anthracyclines [43]
and higher infusion rates are risk factors for anthracycline
cardiotoxicity [10, 19]. The strong association between
cumulative anthracycline dose and cardiotoxicity appears to
be more important with increasing time from treatment
[44, 45]. This relationship was revealed in a study of nearly
15,000 long-term survivors of childhood cancer treated with
anthracyclines who described their cardiac health at up to 30
years after cancertreatment (Figure 1)[ 7]. Otherknown risk
factors for anthracycline cardiotoxicity include younger age
at treatment, female sex, the use of concomitant cardiotoxic
therapies (such as mediastinal radiation), increasing time
since treatment, cardiac injury, as indicated by elevations of
serum cardiac troponin-T (cTnT), neurohormonal activa-
tion of cardiac myocytes in response to pressure and stress,
as indicated by elevations of N-terminal probrain natriuretic
peptide(NT-proBNP),duringanthracyclinetherapy,andHF
during anthracycline therapy [5, 10, 14, 19, 28, 45].
Although not completely understood, genetic predis-
position may also be an important factor in determining
the risk of anthracycline cardiotoxicity [46–48]. Genetic
polymorphisms may alter membrane permeability, antiox-
idant capacity, or metabolism that favors the creation of
cardiac damage. Hereditary hemochromatosis, a genetic
disorder prevalent in individuals of European descent that
can lead to iron overload, is of particular interest because
doxorubicin’s cardiotoxic eﬀects depend, at least in part, on
itsinteractionwithiron.Inmice,Hfedeﬁciency,thedefective
gene in hereditary hemochromatosis, increases the sus-
ceptibility to doxorubicin-induced cardiotoxicity, including
mitochondrial degradation and increased mortality, when
compared to that found in wild-type mice [49]. This fact
suggests that genetic mutations related to defects in iron
metabolism may contribute to cardiotoxicity in humans
although there is currently no literature on the eﬀect in
humans. The concept of genetic predisposition as a risk
factor for cardiotoxicity is further supported by ﬁndings of
greater cardiac susceptibility in patients with trisomy 21 and
black race [50, 51].
Despite the identiﬁcation of these population-based risk
factors, determining the risk for a speciﬁc patient is still dif-
ﬁcult. Therefore, it is important that all children who receive
anthracycline therapy be followed closely, both during and
after treatment for cardiotoxicity.As a guide,the “Long-term
Follow Up Program Resource Guide” [52], developed by
Children’s Oncology Group’s Nursing Discipline Committee
in collaboration with the Late Eﬀects Committee, provides
recommendations for screening and management of late
eﬀects of therapeutic exposures used during treatment for
pediatric malignancies.
4.Monitoring Long-TermCancerSurvivors
4.1. Biomarkers. Although identifying multiple risk factors
has helped to characterize groups at high risk for cardiac
injury, both tolerance of chemotherapy and predisposition
to cardiac damage still vary substantially between patients.
This diﬀerence has led to an increasing interest in the use
of monitoring serum biomarkers as a means of evaluating
cardiotoxicity during and after treatment with anthracy-
clines.4 Cardiology Research and Practice
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Figure 1: Cumulative incidence of cardiac disorders among childhood cancer survivors by anthracycline dose. From Mulrooney et al. [7].
Reprinted with permission from BMJ Publishing Group, Ltd.
4.1.1. Serum Cardiac Troponins. Elevations in cardiac
troponin-T and I (cTnT and cTnI) accurately indicate car-
diac damage, and their presence in serum in any detectable
amount may indicate irreversible cellular necrosis [45, 54,
55]. Cardiac troponin-T is a cardiac-speciﬁc isoform that is
present in cardiac myocytes in both the contractile unit and
the cytoplasm. Serum cardiac troponins are widely used in
diagnosing and managing ischemic heart disease in adults
and also provide valuable clinical information in many other
types of cardiac damage in children [56].
Initial investigations in animal models found dose-
dependent cTnT elevations in response to doxorubicin
administration, elevations that were related to the severity of
histopathologic ﬁndings in cardiac tissue. This relationship
is consistent with the hypothesis that anthracyclines damage
cardiomyocytes, leading to the release of intracellular cTnT
into the circulation [57].
The Dana-Farber Cancer Institute childhood acute lym-
phoblastic leukemia (ALL) consortium protocol 95-001
study found that elevated serum cTnT levels during the ﬁrst
90daysofanthracycline therapy were signiﬁcantly associated
with reduced LV mass and LV end-diastolic posterior wall
thickness as measured by echocardiography 4 years later
[58, 59].
The cardiac contractile protein, cTnI, when present in
the serum, is related to LV dysfunction and increased car-
diovascular risk in adults receiving high-dose chemotherapy
[54, 55] .T h e s eﬁ n d i n g sp r o v i d ee v i d e n c eo ft h ev a l u eo f
serum troponin measurements in childhood cancer patients
receiving anthracyclines.
4.1.2. Serum NT-proBNP. N-terminal probrain natriuretic
peptide is produced during the cleavage of proBNP, a pro-
hormone released from the cardiac ventricles in response to
pressure overload and stretching [60, 61].Chronic elevations
in NT-proBNP indicate increased ventricular wall stress, in
association with pressure overload and elevated diastolic
pressure [62, 63].
The aforementioned Dana-Farber Cancer Institute pro-
tocol 95-001 study also assessed serum NT-proBNP mea-
surements during and after therapy as possible predictors
of cardiac damage. Elevations in NT-proBNP during the
ﬁrst 90 days of therapy were associated with an abnormal
LV thickness-to-dimension ratio 4 years later, suggestingCardiology Research and Practice 5
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Figure 2: Mean left ventricular echocardiographic Z scores in boys and girls (n = 134). Plots are adjusted for age; ∗P ≤ .05 for comparison
of the mean Z score of the doxorubicin plus dexrazoxane group with zero; †P ≤ .05 for comparisonof the mean Z score for the doxorubicin
group with zero; ‡P ≤ .05 for comparisons of mean Z scores between the doxorubicin and doxorubicin plus dexrazoxane groups. From
Lipshultz et al. [53]. Reprinted with permission from Elsevier.
pathologic ventricular remodeling. Additionally, a higher
percentage of children had elevated levels of NT-proBNP
than had elevated levels of cTnT before, during, and after
treatment. This diﬀerence suggests that NT-proBNP may
detect cardiac stress before any irreversible cell damage and
death occurs, which may help identify children early in
therapy who are at increased risk of eventual anthracycline-
related cardiac abnormalities [59].
4.1.3. High-Sensitivity C-Reactive Protein. As a global in-
ﬂammatory marker and a critical component of the immune
system, high-sensitivity C-reactive protein (hsCRP) is widely
used to assess patient health [64]. Systemic inﬂammation
is associated with increased rates of cardiovascular disease
in adults and may also be involved with the mechanisms
underlyinganthracycline-relatedcardiotoxicityandpediatric
cardiomyopathy [65]. As such, elevations in hsCRP may be a
strong indicator of cardiac stress [66].
Despite a small sample size, one study of 19 children
with HF divided into three groups based on symptom
severity found that serum hsCRP levels were associated
with decreased LV function and discriminated between
the diﬀerent groups of symptom severity [65]. Another
study of 156 survivors of childhood ALL showed that
survivors had signiﬁcantly elevated levels of hsCRP when
compared to levels in sibling controls [67]. These ﬁndings
have encouraged further research on the use of serum
hsCRP measurements collected during therapy as potential
predictors of late cardiac eﬀects. Serum hsCRP may prove
to be a valuable screening tool for identifying long-term
survivors at increased risk of subsequent cardiac disease.
4.2. Nanoparticle-Capture Mass Spectrometry. The ability
to identify heart-derived tissue proteins associated with
myocardial injury that can be detected before marked
elevations in cTnT could have profound implications on6 Cardiology Research and Practice
earlier detection and clinical monitoring for doxorubicin
cardiotoxicity. One pilot study using nanoparticle-mass
spectrometry identiﬁedseveralcandidateproteinbiomarkers
previously implicated in cardiac dysfunction, remodeling,
ﬁbrosis, and hypertrophy [68]. Identiﬁcation of these candi-
date biomarkers have the potential to increase the predictive
value of more routinely used markers, such as cTnT,
for earlier detection of cardiac damage, before irreparable
damage and loss of cardiomyocytes occur. However, due to
the small limited sample size, further studies evaluating the
eﬃcacy of nanoparticle-mass spectrometry may advance this
novel diagnostic approach.
4.3. Echocardiography. Several detailed echocardiographic
studies in 115 long-term childhood ALL survivors treated
with doxorubicin have been conducted to better determine
the long-term cardiac status of these patients [14, 69, 70].
These studies, ranging from 6 to 12 years of followup
after treatment, have documented a persistent and progres-
sive restrictive-like cardiomyopathy in long-term childhood
cancer survivors treated with anthracyclines [14, 69, 70].
The restrictive cardiomyopathic-like nature of anthracycline
cardiotoxicity may be of great clinical importance in that
it suggests theories and treatments derived from studies of
dilated cardiomyopathy may be of limited value in under-
standing anthracycline cardiotoxicity throughout life [71].
The ﬁndings of abnormal LV structure and function, as well
as a restrictive-like cardiomyopathic pattern, are consistent
with those of other long-term followup studies conducted
in other groups of anthracycline-treated childhood cancer
survivors [72–74].
5.PreventingAnthracycline-Induced
Cardiotoxicity
5.1. Anthracycline Dosage. Treatment protocols using lower
doses of anthracyclines have reduced the incidence of acute
cardiac complications to less than 1% although chronic LV
dysfunction is still a major clinical concern [50, 53]. In
the 1970s, before the association between higher cumulative
doses of anthracyclines and the greater risk of cardiotoxicity
was known, clinical trials administered cumulative dox-
orubicin doses greater than 400mg/m2 to children with
ALL. Lipshultz et al. found that patients who received
suchhigh cumulativedosesexperienced clinicallyimportant,
progressive LV eﬀects that continued even decades after the
completion of doxorubicin treatment [14, 69, 70]. On the
basis of this experience, cumulative doses of doxorubicin
administered to children and adolescents with ALL were
reduced in the 1980s such that high-risk children received
acumulativedoseofnomorethan360mg/m2,andstandard-
risk children received a relatively low cumulative dose of
no more than 60mg/m2 [58, 75]. Followup of the high-risk
patientssuggestedthatsomerisk ofdelayedLVabnormalities
remained, although the frequency of overt HF was much
lower [14, 69, 70].
In the 1990s, analysis of the combined results of the
Dana-Farber Cancer Institute’s long-term survivors and
those from patients treated in Denmark revealed that after
a median followup of 8.1 years, the risk of LV abnormalities
was lower in patients who received no more than 300mg/m2
than it was in those who received more than 300mg/m2
of doxorubicin [19]. On the basis of those results, the
cumulative doxorubicin dose for high-risk ALL patients
on the Dana-Farber Cancer Institute Protocol 95-001 were
further reduced to 300mg/m2.
5.2. Liposomal Anthracyclines. Structural modiﬁcations of
anthracyclines have been considered as possible cardio-
protection strategies. Of the structural modiﬁcations of
anthracyclines, liposome-encapsulated anthracyclines are
possibly the most promising cardioprotectant. Liposome-
encapsulatedanthracyclinesescapetheleaky capillary system
of tumor sites and as such remain concentrated there, in the
interstitial ﬂuid. They are also less likely to escape the tight
capillary junctions of the heart. This ability to reduce the
plasma levels of free doxorubicin is thought to be the source
ofthereducedcardiotoxicityprovidedbyliposomalformula-
tions of anthracyclines [76]. Although studies of liposomal-
encapsulated anthracyclines are limited in children, biopsies
have conﬁrmed that these anthracyclines have a lower early
cardiotoxicity than conventional anthracyclines [77], and
studies by Marina et al. have helped to conﬁrm their safety
in children [78].
5.3. Treatment with Continuous Anthracycline Infusion. Be-
cause the cellular mechanisms underlying anthracycline
cardiotoxicity are still not completely understood, it has
been theorized thatcontinuousinfusion might providesome
cardioprotective beneﬁt by lowering peak serum levels of
the drug [79]. This theory was supported by ﬁndings from
observational studies in children that found higher dose
rates to be associated with cardiotoxicity, independently
of the eﬀect of total dose [80]. In addition, in adults
receivinganthracyclines,acutecardiotoxicitywasdiminished
in protocols using continuous infusion [81]. On the basis
of these ﬁndings, continuous infusion was incorporated into
many pediatric protocols, despite a lack of evidence on its
long-term cardioprotective eﬃcacy [44, 82].
A randomized controlled trial of continuous (over
48 hours) doxorubicin infusion versus bolus doxorubicin
infusion in 121 high-risk pediatric ALL cases found no
cardiac-related beneﬁt to using the continuous infusion after
amedianof1.5yearsafterdiagnosis[44].Similarresultswere
found after continued followup of this cohort at a median
followup of 8 years [82]. In addition, several retrospective
reviews reported no statistically signiﬁcant diﬀerences in the
echocardiographic characteristics of children with cancer 5
to 7 years after treatment with either continuous infusion
(over 6 to 24 hours) or bolus infusion of anthracyclines
[79, 80].
5.4. Treatment with Dexrazoxane. As mentioned above,
anthracycline-related cardiotoxicity is likely related, at least
in part, to the generation of ROS, which may be exacerbated
by iron-dependent mechanisms [81]. This relationship hasCardiology Research and Practice 7
led to the investigation of several iron-chelating agents, such
as dexrazoxane, for preventing anthracycline cardiotoxicity
[81]. Dexrazoxane is an iron-chelating agent that inhibits
the formation of anthracycline-iron complexes that generate
t o x i ca n dh i g h l yc h a r g e dR O S .H o w e v e r ,o t h e rm e c h a n i s m s
independent of oxidative stress have been proposed as
mediators in the cardioprotective eﬀect of iron chelation
[23], such as the mitigation of DNA damage caused by
dexrazoxane [76]. This proposal has led to great interest
in the use of dexrazoxane in children [83]. Dexrazoxane is
currently recommended by the American Society of Clinical
Oncology for preventing cardiotoxicity in speciﬁc adult
cancer treatment protocols [81].
Fearing that the protection dexrazoxane provides to
cardiomyocytes might extend to cancer cells as well and
perhaps lead to increased rates of second malignancies,
some investigators have been reluctant to use dexrazoxane.
Although such a relationship was previously reported [84],
but questioned [85, 86], in a pediatric Hodgkin lymphoma
trial, no association between dexrazoxane and second malig-
nancies has been found [87].
A randomized controlled trial ofdexrazoxane in children
with ALL treated with doxorubicin used serial cTnT samples
taken during therapy to measure cardiac damage [57]. Of
the 82 children who received doxorubicin plus dexrazoxane,
signiﬁcantly fewer had cTnT elevations when compared
with the 76 children who received doxorubicin alone. The
diﬀerence between groups became even greater over the
course of treatment. After 6 to 8 months, almost 50% of
those treated with doxorubicin alone had an elevated cTnT
level, as opposed to less than 10% of those treated with
doxorubicin plus dexrazoxane. A recent followup report of
this group at a median of 8.7 years found that event-free
survival did not diﬀer signiﬁcantly between the two groups
[53] and that there was no increased risk of recurrence or
second malignant neoplasms [53, 87]. These ﬁndings show
that dexrazoxane can provide long-term cardioprotection
without hindering the eﬃcacy of doxorubicin.
Serial echocardiographic measurements during the 4
years after this trial have also been reported [53]. Children
treated with doxorubicinplus dexrazoxane had progressively
less decreased LV fractional shortening and greater LV
mass and LV wall thickness over time. Most recently, the
protective eﬀects of dexrazoxane reported in this trial appear
to be sex related [53], which is consistent with recent
ﬁndings from animal studies [88]. Females showed the
greatest protective eﬀect from dexrazoxane therapy, while
males receive did not receive such beneﬁt (Figure 2)[ 53].
These ﬁndings further highlight that there is still much to
learn about the mechanisms underlying such diﬀerences
[53, 89] although sex-related diﬀerences in the transport
and clearance of doxorubicin have been reported [90, 91],
as has dexrazoxane cardioprotection against the sex-related
hormone, testosterone [92].
The protective eﬀect of dexrazoxane against anthra-
cycline cardiotoxicity is further supported by studies of
childhood cancers other than leukemia [81, 83]. However,
research is needed to fully understand the subtle risks
associated with the use of dexrazoxane, what methods of
dexrazoxane administration are most eﬃcient, and what
doses are necessary to achieve adequate protection.
5.5. Traditional Cardiovascular Disease Risk Factors. With
more extended followup, the true incidence of chronic
HF in long-term childhood cancer survivors treated with
anthracyclinesmayexceedthereported1%to16%range[44,
93]. Chronic anthracycline cardiotoxicity is not only evident
as symptomatic LV dysfunction, it also frequently manifests
as subclinical abnormalities in LV structure and function. In
some cases, these subclinical changes may progress to HF
and cardiac death. Such eﬀects may also leave long-term
childhood cancer survivors more vulnerable to future non-
anthracycline-related cardiovascular insults.
Long-term childhood cancer survivors, like the general
population, may have one or more of the traditional risk
factors for atherosclerosis, which could provide an additive
risk of future cardiovascular complications beyond that
d i r e c t l yr e l a t e dt oc a n c e rt h e r a p i e s .O b e s i t y ,p h y s i c a li n a c t i v -
ity, tobacco use, and diabetes mellitus are among the most
commonly examined traditional modiﬁable atherosclerotic
risk factors. An improved understanding of the lifetime
cardiovascular risk associated with these factors in long-term
childhood survivors may help guide treatment and predict
any potential additional cardiovascular risk of speciﬁc cancer
therapies, such as the use of anthracyclines [94].
5.5.1. Obesity. In the United States, childhood obesity rates
haveincreasedtowhereithasnowbecomeepidemic[95,96].
Less than 5% of 12-to-19-year-olds were overweight in the
late 1960s, while almost 17% were overweight by the year
2008[96].Thisreportalsoshowsthatalmost32%ofchildren
and adolescents between 2 to 19 years old are at risk of
overweight. One study showed that almost 80% of obese 10-
to-14-year-oldswhohadanobeseparentwereobeseasadults
[97]. This relationship raises two main concerns: (1) child-
hood overweight and obesity are associated with poor health
outcomes, such as coronary artery disease, hypertension,
and diabetes [98] and (2) childhood obesity is strongly
associated with adult obesity, which is associated with an
increased risk of atherosclerotic disease and death. The
American Heart Association’s Childhood Obesity Research
Summit concludedthat: “Obesity contributesto a signiﬁcant
burden in terms of chronic diseases, rising healthcare costs,
and, most importantly, disability and premature death.
It appears that this burden will increase in the future
[99].”
Studies of obesity in long-term survivors of childhood
cancer have found similarly troubling trends suggesting that
survivors may be at increased risk for obesity as a result of
their cancer history. One study compared body fat between
170 pediatric cancer survivors and 71 sibling controls. This
study found that more than one-third of survivors met
the criteria for overweight or obese according to the body
mass index (BMI), but this was no diﬀerent than siblings.
However, male survivors were found to have greater body
fat and trunk fat compared to siblings, while no diﬀerences
were found between female survivors and siblings [100].8 Cardiology Research and Practice
Table 2: Areas for future research in anthracycline cardiotoxicity.a
Basic research Clinical research
(1) Exploration beyond the oxidative stress hypothesis as
a primary mechanism of anthracycline cardiotoxicity
(1) Reduction of anthracycline cardiotoxicity in clinical
practice
(2) Implementation of long-term studies in animal models (2) Identiﬁcation of early signs of cardiac damage
(3) Identiﬁcation of predictive markers of cardiac damage (3) Educate clinicians:anthracycline-induced cardiotoxicity
can initially respond to cardiac medications
(4) Determination of the relative impact of diﬀerent
mechanisms of myocardial damage
(4) Determination of the cardiotoxicity of targeted and
combination therapies
(5) Exploration into the relationship between growth factors
and anthracyclines
(5) Identiﬁcation of a balance between cardiotoxicity with
clinical beneﬁt
(6) Understanding drug interactions in new combination
therapies (6) Deﬁnition of risks and beneﬁts for subgroups of patients
(7) Assessmentof the eﬀects of anthracyclines on cardiac
development
(7) Managementof cardiac dysfunction in cancer survivors
treated with anthracyclines
(8) Assessmentof the eﬀects of anthracyclines on
non-myocyte cardiac cells
(8) Speciﬁcations of dietary and exercise recommendations
for anthracycline-treated patients
(9) Assessmentof risk-beneﬁt factors in groups with
compounding risk factors for cardiomyopathy
(9) Understanding the progression of anthracycline
cardiomyopathy: systolic versus diastolic heart dysfunction
(10) Determination of genetic predispositions to
anthracycline cardiotoxicity
(10) Expansion of the use of dexrazoxane and liposomal
anthracyclines
aData from Gianni et al. [23].
The largest report to date of nearly 8000 long-term survivors
found that about 41% were either obese or overweight
[100]. This study and others also found that despite a high
prevalence of obesity, long-term survivors were not more
likely to be obese than the general population although
certain groups, such as survivors of ALL, were at increased
risk of obesity [101, 102].
The idea that certain subgroups of long-term childhood
survivors are at increased risk of obesity is supported by
studies of those survivors exposed to cranial radiation.
Many of these studies reveal treatment-related damage to
the hypothalamic-pituitary axis, with subsequent growth
hormone deﬁciencyand eventualobesity. However,it should
be noted that not all studies have found such a relationship
and that other factors, such as obesity before diagnosis, may
bemore powerful predictorsofobesity aftertreatment [103].
Itisclear,though,thatobesityishighlyprevalentinsurvivors
of all types of childhood cancer and may predispose this
group to future health problems, especially atherosclerotic
disease, which may be especially problematic for these
patients who are less able to compensate for ischemic cardiac
insults.
5.5.2. Physical Inactivity. Physical inactivity is associated
with higher risk of cardiovascular disease as well as with
other traditional atherosclerotic disease risk factors, such as
insulin resistance and obesity. Physical activity is not only
recommended by several medical associations, including
the American Academy of Pediatrics, but guidelines have
been created by several organizations, including the US
Department of Health and Human Services [104, 105].
Physical inactivity appears to be more common in long-
term childhood survivors than in the general population.
Miller et al. [102] reported that male survivors watched
signiﬁcantly more hours of television compare to siblings.
They also found that increased television viewing hours
was associated with higher BMI and percent body fat in
male and female survivors of childhood cancer. A survey
of nearly 10,000 long-term survivors of childhood cancer
and 3,000 of their siblings revealed that survivors were more
likely than their healthy siblings and the general population
to report being physically inactive and being less likely to
meet recommended physical activity guidelines [106]. This
surveyandothershavefoundthatsomelong-termchildhood
survivors may be unable to comply with these guidelines
as a result of the physical limitations incurred by their
cancer-related surgery or treatment-related cardiac damage.
Hopefully, interventions that lead to appropriate and safe
increases in the physical activity of long-term survivors may
decrease risk of atherosclerotic disease and its associated
negative health outcomes [107].
5.5.3. Tobacco Use. Cigarette smoking is a well-known major
preventable risk factor for cardiovascular disease and all-
causemortalityamongindividualsinthegeneralpopulation.
The increased rate of cardiovascular disease in smokers
has been convincingly evident since the 1960s [108]. One
systematic review of the health behaviors of long-term
survivors found that most studies have reported lower rates
of smoking in survivors relative to the general population
although these ratesare still high enoughto be aconcernand
to warrant intervention [109].
Up to 17% of long-term childhood survivors in the
United States are active smokers, compared to more
than 20% of the general adult population [110, 111].
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smoking may be magniﬁed in long-term survivors who may
already have underlying cardiac abnormalities as a result
of their malignancy and its treatment. Therefore, eﬀorts
aimed at smoking prevention and cessation in long-term
childhood survivors are essential to improve long-term
outcomes [112].
5.5.4. Insulin Resistance. The prevalence of insulin resistance
and overt diabetes has risen steadily and parallels the rise in
the prevalence of obesity and the decline in physical activity.
IntheUnitedStatestoday,almost13%ofadultsaged20years
orolderhave eitherdiabetesor prediabetes, a prevalence that
rose from 5.1% between 1988 and 1994 and to 7.7% between
2005 and 2006 [113].
Diabetes is a major risk factor for cardiovascular disease.
Current recommendations for adults state that the added
cardiovascular disease risk associated with diabetes is equiv-
alent to that of a previous myocardial infarction. A recent
report of more than 8000 long-term survivors found that
t h e s es u r v i v o r sa r en e a r l yt w i c ea sl i k e l yt or e p o r th a v i n g
diabetes as were their siblings [114].
Another longitudinal study of more than 200 long-term
survivors found that 4% had diabetes, another 7% had
impaired glucose tolerance, and another 4% had hyperinsu-
linemia [115]. These ﬁndings are especially worrisome given
that the average age of adult long-term childhood survivors
in the study was 25 years and that all were less than 40
years old, age cohorts that would otherwise would be con-
sidered at low-risk for impaired glucose metabolism. Cancer
treatment-related cardiotoxicity may have left many child-
hood cancer survivors more vulnerable to cardiovascular
disease [44]. Aggressive and early intervention is warranted
to maximally reduce the risk in this population.
5.5.5. Hypertension. Hypertension is among the leading
causes of cardiovascular disease. In 2008, 29% percent of US
adults were hypertensive, an increase from almost 24% in
1988–1994 [116].
Survivorsofchildhood cancerhaveahigherrisk ofdevel-
oping hypertension compared to the general population. A
study of 5,599 childhood cancer survivors and 2,936 siblings
reported that survivors were more likely to report taking
medicationforhypertensionthantheirsiblings(OR1.9,95%
CI 1.6–202) [100].
In addition, a preexisting diagnosis of hypertension fur-
ther increases the risk of clinically signiﬁcant anthracycline
cardiotoxicity [18]. Studies in older adults have shown that
hypertension may work synergistically with doxorubicin
increasing the risk of CHF [117]. Hershman et al. found
thathypertensionintensiﬁedtheeﬀectofdoxorubicinonrisk
of CHF in older adults [118]. Further, studies in rats have
shown a similar trend where hypertensive rats were more
sensitive than normotensive rats to the cardiotoxic eﬀects
of doxorubicin [88, 118]. Therefore, monitoring cardiac
status during and after anthracycline therapy is important,
particularly in the long term, as risks for cardiovascular
disease naturally increase with age.
6.ConclusionsandDirectionsforResearch
Eﬀective anti-neoplastic therapies for childhood cancer are
one of the great successes of modern medicine and have
helped to create a large population of childhood cancer
survivors. However, even years after successfully battling
cancer, many survivors are burdened by the cardiotoxicity
that can result from cancer therapy. There remains a growing
need in both basic and clinical research to better understand
the mechanisms of anthracycline cardiotoxicity, to develop
eﬀective and safe cardioprotection strategies, and to identify
the risk factors for cardiac damage. Table 2 summarizes a
number of the areas where further research could help to
ﬁll the current gaps in knowledge [23]. Most importantly,
cardiologists and oncologists should collaborate to ﬁnd a
balancebetweentherisksofcardiotoxicityandthebeneﬁtsof
oncologictherapytomaximize thequalityoflifeandsurvival
for long-term childhood cancer survivors.
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